Podcasts about Inflation Reduction Act

In August 2022 — just over three years ago — the Inflation Reduction Act was signed into law. It represented the largest federal investment in renewable energy and climate action in U.S. history. The bill was a historic victory for the climate movement — and, as it turns out, its high-water mark in the United States for the foreseeable future. Since returning to office, President Trump has withdrawn the U.S. from the Paris Climate Agreement, rolled back numerous environmental and climate regulations, issued executive orders to pause renewable energy projects, and worked with Congress to dismantle key parts of the IRA.On this episode, Dan Richards speaks with two experts on climate politics at the Watson School: Jeff Colgan, professor of political science and director of Watson's Climate Solutions Lab, and Chris Rea, assistant professor of sociology and expert on climate and environmental governance about the new landscape of climate politics. They discuss the state of the climate movement and green transition in America and around the world, where the climate movement goes from here, and what it all means for our politics and our planet. Learn more about the Watson School's Climate Solutions Lab.Transcript coming soon to our website.

What the U.S. offshore wind power crisis says about energy megaprojects, risk, and political resilience. --- After a surge of optimism, the U.S. offshore wind industry faces its most serious challenges yet. Just a year ago, the sector seemed poised for rapid growth, with East Coast states making offshore wind a centerpiece of their clean-energy and reliability strategies. Today, that progress has been sharply interrupted. The reversal has been swift. Since returning to office, the Trump administration has halted new federal leases and permits and ordered work stopped on projects already under construction, moves that put billions of dollars in investment at risk. By September, Interior Secretary Doug Burgum declared that, under current policy, there is no future for offshore wind in the United States. Yet the industry’s troubles, despite strong progress, began well before this political turn. Inflation, high interest rates, and supply-chain disruptions sharply increased project costs, forcing developers to cancel or renegotiate contracts. Earlier, states had made strategic missteps in their race to capture offshore wind jobs and supply-chain investment, leaving the industry more exposed to shifting economic and policy winds. Elizabeth Wilson of Dartmouth College, founding director of the Irving Institute for Energy and Society, discusses how these experiences have shaped an emerging body of “institutional learning” across the states—lessons in risk sharing, coordination, and governance that may help buttress the industry for the long term. As the future of U.S. offshore wind hangs in the balance, Wilson offers perspective on how those lessons could form the foundation for progress in a political and economic environment that remains volatile and uncertain. Elizabeth Wilson is a professor of Environmental Studies at Dartmouth College and founding director of the Irving Institute for Energy and Society. Related Content Communicating Climate Policy: Raising Public Awareness through Trusted Sources https://kleinmanenergy.upenn.edu/research/publications/communicating-climate-policy-raising-public-awareness-through-trusted-sources/ Bringing Fusion Energy to the Grid: Challenges and Pathways. https://kleinmanenergy.upenn.edu/research/publications/bringing-fusion-energy-to-the-grid-challenges-and-pathways/ Energy Policy Now is produced by The Kleinman Center for Energy Policy at the University of Pennsylvania. For all things energy policy, visit kleinmanenergy.upenn.edu.See omnystudio.com/listener for privacy information.

In Episode 525 of District of Conservation, Gabriella interviews Travis Fisher - director of energy and environmental policy studies at the Cato Institute. Travis discusses his role at Cato Institute, why energy abundance is having a moment, Bill Gates disavowing climate doomerism, challenging the 2009 EPA endangerment finding, if AI data centers are responsible for rising electricity demand, consumer-regulated electricity, and much more. Tune in!SHOW NOTESFollow Travis on X and Cato InstituteThe Fishtank: Free-Market Insights on Energy PolicyCato Institute: The Budgetary Cost of the Inflation Reduction Act's Energy SubsidiesThe Simon Abundance Index 2025A Critical Review of Impacts of Greenhouse Gas Emissions on the U.S. Climate Advocates for Consumer Regulated ElectricityNew Hampshire Sparks a Revolution in Electricity SupplyWhat Would Consumer-Regulated Electricity Look Like?

This week, join Alyssa McNamara Reed, CFP® and her guest Peter D. Stoner of AHIP (American Health Insurance Plans) a Certified Medicare Consultant/Licensed Broker (MA & NH) for a discussion about Medicare Pricing and Considerations. The discussion centers on Medicare coverage, including the different Parts A, B, and D, detailing eligibility, costs, deductibles, and out-of-pocket maximums. A significant portion of the conversation focuses on the complexities and rapidly changing landscape of prescription drug plans (Part D), particularly in light of the Inflation Reduction Act, which has led to higher costs for insurance carriers and fewer plan options for consumers. They also address the current open enrollment period and the challenges consumers face, such as doctors dropping certain insurance plans and the financial implications of high-income brackets on Medicare premiums. Alyssa McNamara Reed is a financial planner with passion for the intersection of taxes and investing.  Alyssa works with motivated savers, beneficiaries of estates, business owners, divorcees, and pre-retirees. About Peter D. Stoner: Over 25 years of Medicare Experience * Manager of Retiree Sales at Tufts Health Plan * Director of Medicare Sales at Fallon Health Plan * Consultant to multiple Medicare Health Plans AHIP (American Health Insurance Plans) Certified https://www.stonermedicare.com/ McNamara Financial is an Independent, family-owned, fee-only investment management and financial planning firm, serving individuals and families on the South Shore and beyond for over 30 years. COME SEE WHAT IT'S LIKE TO WORK WITH A FIDUCIARY. http://mcnamarafinancial.com/

At a moment when our country can feel deeply divided, and when progress on clean energy can feel uncertain, this month's guest — former U.S. Secretary of Energy and two-term Governor of Michigan, Jennifer Granholm — couldn't be timelier.It was the perfect moment to take stock of where we are as an industry. After years of historic progress, we're now facing growing uncertainty about what comes next. The optimism that followed the passage of the Inflation Reduction Act, the Bipartisan Infrastructure Law, and the CHIPS and Science Act can feel harder to access — and yet gatherings like this live recording and New Dawn, our thousand-person sold-out annual party hosted the following evening, remind us how far we've come and how powerful it is when this community comes together.Special thanks to this year's New Dawn Terawatt sponsors, Silicon Valley Bank and Wilson Sonsini, for helping make gatherings like these possible.For me, this interview was personal — and a bit of a full-circle moment. I've admired Governor Granholm for years. We first met over a decade ago, when she served as a judge for one of Powerhouse's early hackathons, and even then, her conviction and optimism left a lasting impression.Her legacy in public service is one of transformation — from rebuilding Michigan's economy to reshaping the Department of Energy's role in accelerating the clean energy transition. At DOE, Granholm led an unprecedented expansion of clean energy deployment and manufacturing, rebuilding supply chains, creating jobs, and helping position the United States as a global leader in the energy transition.In a moment when federal leadership can feel disconnected from what our country truly needs for clean, abundant energy and lasting progress, Governor Granholm is a reminder of what grounded, forward-thinking, and empathetic leadership can achieve. I hope you enjoy this conversation as much as I did.About Powerhouse Innovation and Powerhouse Ventures Powerhouse Ventures backs seed stage startups developing innovative software to advance clean energy, mobility, and industry. If you are thinking about building something in this space, get in touch with our team.Powerhouse Innovation is a best in class consulting firm, powered by the strongest energy innovation network, data and team in our industry. We partner with world's leading corporations, investors, and utilities to source and evaluate disruptive startups shaping the future of energy and industry.To hear more stories of founders building our energy abundant future, hit the “subscribe” button and leave us a review.

This episode is Part 2 of a 2-part Medicare Series on the Senior Matters Podcast, hosted by Mark E. Wight with guest Chad McDonald, Medicare Specialist of CRM Group, LLC. Now, in Part 2, Medicare Premiums and Enrollment Changes, Mark continues the conversation with Medicare expert Chad McDonald to break down what's happening for Idaho seniors in 2026. Medicare Part B premiums are increasing from $185 to $206, but the biggest challenge is widespread plan exits and shrinking benefits. Up to 84,000 Idaho Medicare beneficiaries will lose their current plans, forcing them to act during the Special Election Period (Oct 15–Dec 31) to avoid coverage gaps. Chad explains how new federal rules and the Inflation Reduction Act reimbursement cuts are reshaping the market, leading carriers to eliminate extra benefits like dental, vision, and fitness memberships in favor of essential medical coverage. You'll learn: How to manage premium increases on a fixed income What the plan exits mean for Idaho seniors Why early review of your Annual Notice of Change (ANOC) is crucial How to avoid losing coverage during this transition Chad shares proactive strategies for enrollment, plan review, and agent collaboration, emphasizing the importance of early action and trusted advice.

In this podcast, Adam Peters, CEO of Air Liquide North America, joins Jeremy Osterberger to talk about the company's growing investment in the United States and its role in the transition to cleaner industry. Peters explains why the U.S. continues to attract large-scale projects, how trade uncertainty and tariffs affect global planning, and why policy stability—especially under the Inflation Reduction Act—is key for hydrogen expansion. He also shares how Air Liquide is helping manufacturers cut emissions while strengthening competitiveness, and offers a personal look at his own journey from upstate New York to Texas. For more news on the renewable energy industry, manufacturing industry, oil and gas industry and more, visit bicmagazine.com. This podcast is sponsored by TankWorx and Construction Services.  Discover how TankWorx and Construction Services can help you build safer, stronger, and smarter. Visit tankworx.com to learn how their expertise can power your next project.

Originally uploaded August 13th reloaded October 26th. Jeffrey Mosher welcomes Cory Connolly, Chief Climate Officer, EGLE ( Michigan Department of Environment, Great Lakes, and Energy), Lansing, MI. About: $129 Million Federal Investment Accelerates Michigan's Clean Energy Initiatives What is the Renewable Ready Communities (RRC) Program and why should Michigan residents care about it? How will this investment by the EPA accelerate the deployment of renewable energy projects in the state and how could it change the future of Michigan? Can you elaborate on the partnership with the Michigan Department of Labor and Economic Opportunity to ensure Michigan has the workforce to meet 2030 renewable energy goals? How will this support jobs? How will this investment help Michigan achieve the goals of the MI Healthy Climate Plan? What are other investments and projects EGLE is championing to support the roll out of clean energy? » Visit MBN website: www.michiganbusinessnetwork.com/ » Subscribe to MBN's YouTube: www.youtube.com/@MichiganbusinessnetworkMBN » Like MBN: www.facebook.com/mibiznetwork » Follow MBN: twitter.com/MIBizNetwork/ » MBN Instagram: www.instagram.com/mibiznetwork/ The EPA has awarded Michigan $129 million from the Inflation Reduction Act's Climate Pollution Reduction Grant (CPRG) program. This investment will accelerate the deployment of renewable energy projects, helping Michigan achieve its climate goals while fostering economic growth and job creation. This funding will allow the state to launch Renewables Ready Communities (RRC), administered by the Michigan Department of Environment, Great Lakes, and Energy (EGLE). The RRC has five priority areas: Expanding the Renewables Ready Communities Award pilot, an initiative launched in 2024 with a one-time state investment of $30 million, that provides financial incentives, on top of tax revenue and community benefits, to local and tribal governments that approve and host utility-scale renewable energy and energy storage through local processes. Creating the Brownfield Renewable Energy Pilot program to provide grants for renewable energy projects on brownfields, incentivizing deployment on brownfields. Strengthening EGLE's Renewable Energy Academy to develop technical assistance for local and tribal governments to improve planning, siting, and permitting processes for renewable energy facilities and the new Brownfield Renewable Energy Pilot program. Supporting workforce development programs, in coordination with the Michigan Department of Labor and Economic Opportunity, to ensure Michigan has the workforce needed to build enough renewable energy to meet the state's 2030 goals. Developing a Renewables Ready Communities Strategic Plan to ensure a comprehensive strategy for utility-scale and brownfield renewable energy projects to meet the state's 60% renewable energy by 2030 goals. Governor Gretchen Whitmer announced the U.S. Environmental Protection Agency (EPA) has awarded the State of Michigan $129.1 million from the Biden-Harris administration's Inflation Reduction Act's (IRA) Climate Pollution Reduction Grant (CPRG) program to accelerate the deployment of renewable energy like wind, solar, and storage. The investment will help Michigan meet its 60% renewable energy and 100% clean energy standards set under the recently enacted clean energy laws. Getting this done will create good-paying jobs, drive down energy costs, and protect the state's air, land, and water. “Michigan is committed to leading the future of clean energy so we can drive down utility costs for families, create good-paying jobs, and grow our advanced manufacturing economy,” said Governor Whitmer. “Thanks to our congressional delegation and the Biden-Harris administration's investment in Michigan, we are ready to launch the Renewables Ready Communities Program to meet our renewable energy and MI Healthy Climate Plan goals.

In this episode of Smart Energy Voices, host Debra Chanil presents a special double header from the recent SED Forum Fall, examining how recent U.S. policy changes are reshaping the clean energy landscape. Stanley Reynolds, Professor Emeritus of Economics at the University of Arizona, unpacks the “One Big Beautiful Bill” (OBBB) and its reversal of key Inflation Reduction Act incentives. He outlines the bill's potential economic impacts, including higher energy costs and reduced investment, while also pointing to reasons for optimism like competitiveness in the renewables space and continued innovation. Peter Kelly-Detwiler, Principal at NorthBridge Energy Partners, continues the discussion with insights on navigating this environment. He highlights the industry's resilience, the growing role of breakthrough technologies like geothermal and modular nuclear, and strategies for energy buyers to adapt amid uncertainty and opportunity. You will want to hear this episode if you are interested in… Overview of the One Big Beautiful Bill and its economic impacts (03:16) Key provisions of the OBBB, including rescinded IRA funds (04:09) Forecasts for energy prices, investment, and jobs (10:45) Opportunities in renewables, innovation, and state-level policy (13:01) Arizona as a case study for policy impacts and opportunities (15:55) Status of major offshore and onshore projects post-OBBB (20:08) Emerging technologies like advanced geothermal (25:04) Rising electricity demand from data centers and electrification (30:14) On-site generation and geothermal systems as near-term solutions (34:38) Legal, ESG, and financial considerations for energy buyers (38:10) For full episode show notes, click here. Connect with Stanley Reynolds On LinkedIn Stanley Reynolds joined the University of Arizona after earning a doctorate in Economics from Northwestern University. He has served as Economics Department Head and Vice Dean of the Eller College of Management at U. of Arizona. His areas of expertise include energy economics, environmental economics, and industrial organization. His research has been published in leading economics journals such as Econometrica, Quarterly Journal of Economics, and the Rand Journal of Economics. His current research examines the economics of grid-scale energy storage, the impact of environmental policy on energy markets, and integration of renewable energy into the electric grid. Connect with Peter Kelly-Detwiler On LinkedIn Peter Kelly-Detwiler has 30 years of experience in the electric energy industry, with much of his career in competitive power markets. He's currently a leading consultant in the electric industry, providing strategic advice to clients and investors, helping them to navigate the rapid evolution of the electric power grid. Mr. Kelly-Detwiler offers numerous keynotes and workshops on a wide range of topics. He has also written widely on energy issues for Forbes.com and GE, with over 300 articles to his credit. His book on the transformation of electric power markets – “The Energy Switch” – was published by Prometheus Books in June of 2021. Connect With Smart Energy Decisions Smart Energy Decisions Follow us on LinkedIn Subscribe to Smart Energy Voices on Apple Podcasts, Google Podcasts, Android, Spotify, Stitcher, TuneIn Radio, aCast, PlayerFM, iHeart Radio If you're interested in participating in the next Smart Energy Decision Event, visit smartenergydecisions.com or email our Community Development team at attend@smartenergydecisions.com

On Tuesday's Mark Levin Show, Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Also, Democrats are keeping the government shutdown by continuing to block a non-controversial continuing resolution to try and blackmail Republicans to approve $1.5 trillion in additional spending. This will generate massive debt—similar to the phony Inflation Reduction Act—leading to inflation, higher prices for gasoline, food, mortgages, and credit cards, ultimately harming average citizens and future generations. Later, Zohran Mandami must be defeated in New York's upcoming mayoral race. He dodges questions on Hamas support; campaigns with Imam Siraj Wahaj, who served as a character witness for the 1993 World Trade Center bombing mastermind and called for jihad. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The One Big Beautiful Bill Act (OBBBA), signed into law July 4, expanded restrictions on Foreign Entity of Concern (FEOC) rules established by the Inflation Reduction Act in 2022. In this latest installment of the Renewable Energy Tax Credit Finance Series, Novogradac partners Tony Grappone, CPA, and Nicolo Pinoli, CPA, dive into the evolution of FEOC rules and how they affect a project's eligibility for renewable energy tax credits (RETCs). They then clarify the difference between types of prohibited foreign entities and identify key FEOC compliance issues of which developers and investors should be aware. Finally, they review the timeline of effective dates, as well as the penalties and recapture risks for non-compliance.

LISTEN and SUBSCRIBE on:Apple Podcasts: https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608 Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i WATCH and SUBSCRIBE on:https://www.youtube.com/@WatchdogOnWallstreet/featured  Welcome to the only business where failure makes you richer — American politics.In this episode:How the climate “crisis” became the biggest financial fraud in historyWhy New Jersey's Phil Murphy turned his state from an energy exporter into a power-price disaster zoneThe truth behind those “clean energy” checks politicians keep cashingFrom Obama's Reinvestment Act to Biden's Inflation Reduction Act — how the grift just keeps getting greenerAnd why voters keep falling for it, one virtue-signaling post at a timeStupid pays — and the politicians laughing all the way to the bank prove it.

with Brad Friedman & Desi Doyen

Dr. Monty Pal and Dr. Fumiko Chino discuss several of the top abstracts presented at the 2025 ASCO Quality Care Symposium, including research on federally funded clinical trials and financial reimbursement for trial participation. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we are highlighting key abstracts that were presented at the 2025 ASCO Quality Care Symposium. I am delighted to be joined today by the chair of this year's meeting, Dr. Fumiko Chino. Dr. Chino is an associate professor in radiation oncology at MD Anderson Cancer Center with a research focus on access, affordability, and equity. She is also a consultant editor of JCO Oncology Practice and the host of the Put into Practice podcast. I have got to listen to that.  Dr. Chino, welcome, and thanks so much for being on the podcast today. Dr. Fumiko Chino: I am overjoyed to be here, and absolutely, you should take a listen. Dr. Monty Pal: Definitely. And FYI for listeners, our full disclosures are all available in the transcript of this episode, so do have a look if you are inclined. Now, we have really seen some fantastic advances in health services and quality and supportive care, digital health, and beyond. There are some great abstracts that were presented at this year's meeting. I have actually picked a couple that I am particularly interested in and that I believe you share my interest in as well.  So, the first is an abstract actually from my friends at SWOG (Abstract 94). So, this was a terrific abstract from Joe Unger and Michael LeBlanc and Dawn Hershman. And this, I think, really hits on a very, very key issue right now, which is the benefit of federally funded trials. Do you mind just kind of spelling out some of the observations from what I think is a really brilliant piece of work? Dr. Fumiko Chino: Absolutely, and I think Dr. Unger's work is really important for our current funding environment. I think that this research is really essential to do to show the role of federal sponsorship in the design and conduct of clinical trials. Because what they did was really look at a landscape analysis over the last 20 years looking at funding and were able to show quite clearly that federal funding really matters for advancing the science in cancer care. So what they showed was that the federal funding was more commonly essential for early-stage clinical trials, so those phase 1, phase 2 trials that really help advance the science. And that federal funding was really essential for multimodality drug combinations, combinations with drug and surgery, combinations with drug and radiation. Those trials were much more likely to be federal funded. And then the last thing is that they showed that the patients that are, I think, the largest at risk for gaps in care who really need the advancements in science that keep U.S. health care amazing and wonderful and world-leading, so the kids, the pediatric patients, the patients with rare cancers, and the patients actually that could benefit from de-escalation or right-sizing of treatment, they were also all more likely to have federal funding. So I think this research that was presented really shows that if, unfortunately, current status of restricted federal funding continues, that we are going to lose out in terms of the next generation of cancer cures, cancer de-escalations, and the type of combination treatments that make advancements in science. Dr. Monty Pal: Indeed. You know, I always point to Joe Unger's paper, and I think it is in JAMA Oncology, right, that showed life-years gained from NCI trials. It is such an important piece of work. I think this is a really nice complement to that, isn't it, to show the specific areas that otherwise would be, am I right in saying, kind of largely untouched? Dr. Fumiko Chino: I think you are right in that what we know from what industry will sponsor versus what the federal government will sponsor, that the federal government really helps make up the gap to really make those advancements that save lives, that lead to more birthdays, that advance our knowledge and our capacity for providing more cures and more successful futures for our patients. I always like pointing to the de-escalation research, which is, and this is not to dig pharma, but no pharmaceutical company is going to run a trial that says you can give less of their drug, right? It just does not make sense for the business end of the science. And so, thinking about how to right-size treatments, how to do more with less, that really is the purview of the federal government. Dr. Monty Pal: Absolutely. Absolutely.  I am going to shift gears here and bring up another abstract that I found to be quite intriguing, and this relates to reimbursement of expenses, et cetera, for clinical trials. This is an abstract from Courtney Williams and team. It brings to mind the importance, I think, of recognizing the hardships that patients take on by clinical trials, but I also would love for you to comment on that sort of fine line between reimbursement for expenses and then, you know, sort of undue enticement. It is a challenging balance there. But give me your reflections on this abstract. Dr. Fumiko Chino: Absolutely. You are speaking about Dr. Williams' Abstract 93 from the Alabama group, and Alabama actually has this incredible group of health services researchers which is, are doing really important work in this space. What this trial shows is that, you know, it is a small pilot study, it is 30-something patients that received some support primarily for their travel and additional expenses related to their clinical trial participation for breast cancer. It showed that the money helps, and I think what we all know is that it is expensive to participate in clinical trials. It requires additional visits. It often requires some significant travel burden for our patients, and I do not feel that money reimbursement for clinical trial expenses is an inducement. Nobody participates in a clinical trial to get the money for their gas, right? We know that our patients are making some pretty significant sacrifices in order to participate in clinical trials, and what this type of program does is just actually reimburse them for their outlaying of funds.  And I loved this trial because the patients were actually given $1,000 a month for the first 4 months of their trial participation, and what the study showed is that the patients were using it for things like travel-related food, for things like transportation, caregiver expenses, or even some of their out-of-pocket medical expenses like cost sharing or prescriptions. And that they said that overall, the reimbursement really made a difference in terms of their capacity for staying on the clinical trial. Because we know our clinical trials really are not able to enroll the full diversity of patients that often have a disease, and that the patients that are at biggest risk for a health care disparity or a gap in care are also the least likely to enroll in a clinical trial.  Programs like this are an essential part of showing how financial toxicity can be overcome with pretty straightforward assistance to patients to help reimburse them for the things that they are already taking out of their pocket, for parking costs, for that $10 soup that they buy at the cancer center, for those additional expenses that we are, unfortunately, putting on them. Dr. Monty Pal: Very well said. And you know, I have started to dabble in clinical trials looking at CAR T-cell therapies for kidney cancer, and I have to tell you, it is just insane the amount of cost that a patient would have to take on to comply with the stipulations for some of these novel therapies. We require that they stay within 30 minutes of the facility for 28 days, and unless we are compensating for some of that, I mean, how can one afford a hotel stay that is that long? I mean, it is just, it is unprecedented, and it would certainly provide a huge barrier to many patients who would otherwise enroll. Really well said. I also wanted to bring up another financially driven topic, and treating renal cell, again, I would say the vast majority, 90% plus of my patients in clinic are on oral drug therapies. And I cannot tell you how often a patient will show up in my practice and say, "Doc, I have got 15 days out of this 30-day prescription left. What do I do with it?" You know, or some come with pill bottles from a deceased loved one. And it is so frustrating to say, "Take it to the pharmacy and they will just get rid of it for you." But sounds like there is an abstract from Dr. Mackler, Abstract 102, that seems to address this topic quite well. Am I right? Dr. Fumiko Chino: Absolutely. This presentation, I was the most excited about seeing because this group, which helps run a cancer drug repository, theirs is called YesRx, presented their data from the last approximately two years of running this repository, and they were able to show incredible benefit for their patients in Michigan. And it is a really straightforward program. It is run by pharmacists. It has support from the legislation in Michigan. And what they were able to show is that they repurposed medications that would otherwise have been discarded. They delivered them directly to the oncologist, which then actually dispersed them to the patients. They helped 1,000 patients in less than two years. They saved them millions of dollars, over $15 million presented in the abstract. And it is just a win-win-win because I know that patients actually, and sometimes patient caregivers, they feel very sad to have spent a lot of money out of pocket for their medication, and then if they have a dose reduction or, obviously, you know, if the surviving spouse then has to get rid of their medication, just dispose of them, it is very disheartening. And this is a way of kind of reclaiming power for patients. So they were able to accept donations from all over the state of Michigan and then also help over 1,000 patients. And so, it is a phenomenal program. Dr. Monty Pal: Just wild when I came across the dollar amounts, right, that they were saving. It just, it seems like a place that, you know, we just have to look, as cancer centers, right, and really take this on. Just brilliant. On that same theme of cost savings and so forth, you know, I think there has been a lot of focus on what recent policies have done in the context of us having access to therapies and so forth. And one of the topics that has come up is the Inflation Reduction Act and how changes pertaining to the IRA have really played a role in one's ability to take on some of these expensive prescriptions. And I believe John Lin and colleagues tackled that issue in Abstract 97. Could you comment on that, Fumiko? Dr. Fumiko Chino: Absolutely. Dr. Lin is one of my colleagues here at MD Anderson, so I know him very well, and he has been doing really phenomenal work over the last several years with looking at drug affordability and access. And what his analysis shows is that for patients, after the Inflation Reduction Act's cap on out-of-pocket expenses, is that it really did show that out-of-pocket expenses decreased. So what the Inflation Reduction Act did is that it eliminated the 5% co-insurance and placed this $2,000 cap on out-of-pocket expenses. And what that led to for these patients that were not able to have the low-income subsidy is that there were lower costs, and that there was a lower rate of drug abandonment, meaning that the prescription was not refilled. There was also a lower rate of unfilled prescriptions as well. And I think that it shows that health policy really can improve access to care. I think the flip side of the fact that the IRA, this policy, really did seem to help people is that what his research showed is that actually, even with the benefits of this cap, is that actually it is still really high in terms of the rate of people who are not able to fill their prescriptions or that completely abandon them over time. And that unfortunately, even with this change, that over half of people without the low-income subsidy were potentially not getting the full benefit of their medications because they were not able to afford them. And so I think it really kind of highlights that we still need to do more work about making drugs affordable. Dr. Monty Pal: Indeed, indeed. And I mean, in a setting like this, I mean, I think it is important to recognize that $2,000 is a lot, it is a big chunk of change, right, for a lot of families in the U.S. What do you think of the prospect of, like, decreasing that cap? Is that something that from a policy standpoint you would be supportive of? Dr. Fumiko Chino: Well, so something that is a real option for patients on Medicare is there is something called the Medicare Prescription Payment Plan, and what it allows you to do is actually prorate the $2,000 over the whole year. And so instead of having to pay $2,000 as soon as you fill your prescription, because you are going to have, if you have an expensive medication, it is essentially you have to pay the $2,000 in January, right? It allows you to prorate it, so essentially $170 a month, and that comes to you as like a regular bill. And I think that as rolled out as part of the IRA is a really lovely way of thinking about how do we make these payments more stable over time, so it is not a huge hit sort of at the beginning of the year. And I think that alone actually can make a difference in terms of trying to help make sure that people can actually get their medications. Dr. Monty Pal: That is an excellent tip. Excellent tip.  We are going to shift gears entirely. We have been talking a lot about the dollars and cents of things and talk about an abstract from Sophia Smith and colleagues. So this is Abstract 550 at your meeting. And this hinged on a program of sorts to deal with post-traumatic stress disorder. We do not often think about PTSD in the vernacular for oncology patients, but indeed, I mean, it is something that they must face, especially in the context of long-term survivorship. Can you talk a little bit about Dr. Smith's abstract? Dr. Fumiko Chino: Absolutely. I love this work from Dr. Smith, who is at Duke. She worked with Dr. Applebaum, who was my old colleague at Memorial Sloan Kettering. And this group of researchers really is trying to figure out how to best support people into survivorship so that they can actually thrive. And their patient population for this work was actually people who received stem cell transplant, and they focused on people who had PTSD symptoms. And what they were able to show through this SMART design, which is essentially this serial, multiple randomized trial, so everyone got randomized upfront to either usual care or this app, so this digital app that actually helped coach people through cancer distress. And then for the people who were non-responders, they were then additionally randomized to either the app plus coaching or a therapist versus the cognitive behavioral therapy or CBT.  And what they were able to show is that, number one, anyone who had the app seemed like they did better than those who did not start the path with the app. But then the additional help of either the therapist or the coach or the CBT made additional benefit over time. And so, I think this shows a really nice stepped care, which is you can potentially have some right-sizing of treatments cost saving, if we sort of give everyone the app, which is, I think, overall pretty low cost. And that for the people who do not get the full benefit from the app, then you can think about these maybe more tailored approaches, the therapist, the coach, the CBT, but that some people actually just respond to the app. And I think it allows us to, again, right-size the care for our patients. And I think it is really innovative to think about how technology can help improve access to care in the setting of something like PTSD. Dr. Monty Pal: Brilliant summary. Brilliant summary.  Gosh, it looks like such an exciting meeting this year. Congratulations on a terrific program for the ASCO Quality Care Symposium. I know you played a huge role in developing it, and thanks for sharing your insights on the ASCO Daily News Podcast. Dr. Fumiko Chino: No, I really appreciate you having me. ASCO Quality is my favorite meeting of the year. You know, it is really a phenomenal meeting, and I am so excited for next year in Boston in 2026. Dr. Monty Pal: Awesome. And thanks to our listeners too. You are going to find links to all the abstracts that we discussed today in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. More on today's speakers: Dr. Sumanta (Monty) Pal  @montypal Dr. Fumiko Chino @fumikochino Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures of Potential Conflicts of Interest: Dr. Monty Pal:     Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Fumiko Chino:  Consulting or Advisory Role: Institute for Value Based Medicine Research Funding: Merck

Join host Sean White as he interviews Jason Evans, co-founder and Chief Innovation Officer at ProScore Technologies, about the transformative role of AI in workforce management for the renewable energy sector. Discover how ProScore's innovative solutions streamline compliance with the Inflation Reduction Act, simplify onboarding for contractors and subcontractors, and support apprenticeship programs across the industry. This episode offers valuable insights into prevailing wage compliance, high-paying career opportunities, and the future of technology-driven workforce solutions in clean energy.   Topics Covered ProScore Technologies IRA = Inflation Reduction Act Constructors and Subcontractors Apprenticeship Program Incentives Tax Credits E-Learning EPC = Engineering, Procurement and Construction AI = Artificial Intelligence ASES = American Solar Energy Society Big Beautiful Bill Prevailing Wage Davis-Bacon www.sam.gov ProScore Connect Solar Apprenticeship Program   Reach out to Jason Evans here: LinkedIn: www.linkedin.com/in/jason-evans Website: www.proscore.ai   Learn more at www.solarSEAN.com and be sure to get NABCEP certified by taking Sean's classes at www.heatspring.com/sean www.solarsean.com/pvip www.solarsean.com/esip

Austin homeowners can save big on 2025 water heater replacements with $800 local rebates, federal tax credits up to $2,000, and new Inflation Reduction Act programs launching in 2025. Mr. Rooter Plumbing of Austin City: Austin Address: 12201 Roxie Dr Website: https://www.mrrooter.com/austin

    On this episode of The Ty Brady Way, Ty breaks down the current state of the health insurance industry and why so many agents and consumers are feeling the turbulence. From the Inflation Reduction Act's changes to Medicare drug plans and the rising cost of care, the ripple effects are hitting carriers, doctors, and members alike. Ty speaks about why PPOs are leaving markets, the differences between HMOs, PPOs, and Medicare Supplements, and why commission cuts are happening. Ty also shares insights on common pain points like dental coverage, prescription drug costs, and how to help members navigate plan changes without unnecessary frustration. While the headlines may sound grim, this episode reminds us that change is constant — and with change comes opportunity. By focusing on education, resetting strategies, and putting members first, agents can not only adapt but thrive in this new landscape.     As always, we would like to hear from you! Email us at thetybradyway@gmail.com Or DM us on Instagram @thetybradyway https://www.instagram.com/thetybradyway/

The IRS says 46% of its workforce will be furloughed as the government shutdown stretches into its second week. The move marks a sharp reversal from last week's plan to keep operations open using Inflation Reduction Act funds. Union President Doreen Greenwald warns taxpayers to expect longer wait times, backlogs and delayed refunds — calling it “another day of frustration for taxpayers.” Subscribe to our newsletter to stay informed with the latest news from a leading Black-owned & controlled media company: https://aurn.com/newsletter Learn more about your ad choices. Visit megaphone.fm/adchoices

With federal funding being pulled back, leaders of Pennsylvania’s top labor unions push state policy to deliver clean energy jobs. --- For generations, union members have mined Pennsylvania’s coal, run its power plants, and built its energy infrastructure, helping make the state a top fossil fuel producer and electricity exporter. Now, renewable energy offers the promise of growth, but questions remain about the long-term jobs it will provide. In 2024, the Pennsylvania AFL-CIO and the Building and Construction Trades Council formed Union Energy, with support from the Climate Jobs National Resource Center. The coalition was launched to leverage the Inflation Reduction Act to ensure new clean energy investment creates good-paying union jobs and broad community benefits. But with federal funding now being pulled back, state policy is now central. In Pennsylvania, where clean energy targets haven’t been updated in two decades, Governor Josh Shapiro has proposed a “Lightning Plan” with new standards, a cap-and-invest program, and streamlined permitting. Union Energy wants to help shape what comes next. On the podcast, Union Energy’s leaders — Angela Ferritto, president of the Pennsylvania AFL-CIO, and Robert Bair, president of the Pennsylvania Building Trades — discuss the impact of recent policy shifts on their members, policies to expand clean energy with strong labor standards, and their vision for Pennsylvania’s energy future. Related Content: Bringing Fusion Energy to the Grid: Challenges and Pathways https://kleinmanenergy.upenn.edu/research/publications/bringing-fusion-energy-to-the-grid-challenges-and-pathways/ Navigating Tensions in Just Energy Transitions https://kleinmanenergy.upenn.edu/research/publications/navigating-tensions-in-just-energy-transitions/ U.S.-China Competition in the Age of Trump’s Energy Law https://kleinmanenergy.upenn.edu/commentary/podcast/u-s-china-competition-in-the-age-of-trumps-energy-law/ Energy Policy Now is produced by The Kleinman Center for Energy Policy at the University of Pennsylvania. For all things energy policy, visit kleinmanenergy.upenn.edu. See omnystudio.com/listener for privacy information.

In this week's episode, host Daniel Raimi discusses carbon removal with Jennifer Wilcox, a professor at the University of Pennsylvania who recently coauthored a paper titled, “Elevating Carbon Management: A Policy Decision-Making Framework and Rubric for the 21st Century.” Wilcox discusses the existing gaps in current policies related to carbon removal and important considerations when amending and creating new policies. She also addresses the recent change to the 45Q subsidy (originally included in the Inflation Reduction Act of 2022 and revised by Congress in the budget reconciliation bill signed on July 4, 2025), assessing how the updated tax break offers incentives for carbon removal. “Elevating Carbon Management: A Policy Decision-Making Framework and Rubric for the 21st Century” by Jennifer Wilcox, Noah Deich, and Holly Jean Buck; https://kleinmanenergy.upenn.edu/research/publications/elevating-carbon-management-a-policy-decision-making-framework-and-rubric-for-the-21st-century/ National Park Service Rehabilitation Tax Credits; https://www.nps.gov/subjects/taxincentives/index.htm

We welcome back Josh Kinzel from Seniority Benefit Group for his sixth visit to the podcast. The focus of this conversation is on the upcoming changes to Medicare enrollment and coverage for 2026, as well as practical advice for those approaching or currently navigating Medicare options.Breaking Down the Medicare Alphabet SoupJosh walks us through the parts of Medicare and why understanding them is so important:Original Medicare includes Part A (hospitalization, generally free) and Part B (outpatient coverage, with a monthly premium).Original Medicare typically covers 80% of approved costs, but there's no out-of-pocket cap for the leftover 20%. That's where the choice between a Medicare Supplement (Medigap) plan and a Medicare Advantage (Part C) plan comes in.Medigap fills in gaps left by Original Medicare—giving simplicity and freedom to see almost any provider accepting Medicare. You add on a Part D drug plan for prescriptions.Medicare Advantage plans are administered by private insurance companies. The government pays these companies on your behalf, so the advertised zero-premium plans are real—but always remember, your Part B premium still applies. With Advantage, you're often in an HMO or PPO network, may have to seek pre-approval for some services, and pay more out of pocket if major health issues arise.What's New for Medicare in 2026?As usual, we're recording before all federal rules are final, but here's what we know:Part B premiums are expected to rise by about 11%, reaching an estimated $206.50 monthly.Part D drug plan costs may inch up, mainly as insurers adjust to the new $2,000 annual out-of-pocket limit (from the Inflation Reduction Act). While deductibles and catastrophic thresholds rise, costs for many drugs, especially for diabetes, are actually dropping.The infamous “donut hole” coverage gap is now virtually gone, making prescription coverage simpler.Talk continues about longer-term Part D and Advantage contracts (potentially covering more than one year) and the introduction of more pre-authorization (prior approval) steps, including the use of AI to address fraud and control costs.Medicare Advantage and the “Free” Plan QuestionA recurring theme is whether Medicare Advantage's free or low-cost plans are really “free.” Josh explains that these plans are genuinely $0 premium because the government subsidizes them, but you'll still pay the Part B premium, plus out-of-pocket costs when you use services. The trade-off is less predictability, more restrictions on doctor/hospital networks, and a risk of higher costs if you need significant care.If you like this episode, please let us know. We appreciate the feed back, and your support of offset costs of producing the podcast!MyCare Ohio: A New Managed Care Option for Dual EligiblesWe explore MyCare Ohio, a managed care model that combines Medicaid and Medicare benefits for those who qualify for both. Expanding to all 88 counties in Ohio, this program promises consolidation, fewer cards to carry, and—potentially—lower out-of-pocket costs for those with low income and assets. Eligibility, plan availability, and making sure your doctors are in-network are important considerations.How Employers and Retirees Fit InFor people who are still working at 65 or have retiree health coverage, we emphasize comparing employer plans with Medicare options—never simply assuming your current coverage is best. Employers can use experts like Josh's group to help employees or retirees make smart,...

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

CCL volunteers put a lot of work into pushing the clean energy tax credits within Inflation Reduction Act over the finish line to be signed into law in 2022, and into protecting some of its provisions from outright repeal in the big budget bill this year. But how much did our efforts achieve for the climate? Join CCL Research Manager Dana Nuccitelli for an exploration of modeling scenarios in an effort to quantify how much climate pollution CCL volunteers' efforts succeeded in preventing in our pursuit to preserve a livable climate. Skip ahead to the following section(s): (0:00) Intro & Agenda (2:25) A Stroll Down Memory Lane (9:59) Emissions Heading Down (12:01) Since The Election  (21:44) What Did We Achieve? (29:31) How to get the Next Billion Tons Presentation Slides: https://cclusa.org/ira-achieved 

Become a paid subscriber to our newsletter/podcast, The Climate Weekly, to help support this show! It's fun. All the cool kids are doing it! First, the conversation was centered on The Green New Deal. Then, Build Back Better, which turned into the Inflation Reduction Act. It was passed. A few years later, major climate provisions in the bill were repealed. It was fairly popular, but mostly unknown to the average American. So what have we learned? Is it possible to advance major climate policy in America? Our guests today say yes. And they have a new, comprehensive, ambitious plan at the core of their argument. Joining us is Saikat Chakrabarti, co-founder and president of New Consensus and candidate for Congress in the Democratic primary against Nancy Pelosi. Previously, he worked on the 2016 Bernie Sanders presidential campaign, co-founded Justice Democrats, and was the campaign manager and then Chief of Staff to Rep. Alexandria Ocasio-Cortez where he led the effort to draft and release the Green New Deal. We're also joined by Zack Exley, co-founder and the executive director of New Consensus. Previously, he co-founded Justice Democrats, led the national distributed organizing team on Bernie Sander's 2016 presidential campaign. and helped shape the U.S. Green New Deal. Zack also spearheaded online small-dollar fundraising at MoveOn.org and worked on the Howard Dean and John Kerry campaigns in 2004. In this episode we explore why ambitious policy aims are so critical to the moment, what it means for democracy, how it will combat high electricity bills, and the lessons learned from the Green New Deal. Their plan is Mission For America, which focuses heavily on climate policy to organize a massive plan to grow jobs and lower prices. This is a great conversation.  Please consider becoming a paid subscriber to our newsletter/podcast, The Climate Weekly, to help support this show. Your contributions will make the continuation of this show possible.  Our music is "Gotta Get Up" by The Passion Hifi, check out his music at thepassionhifi.com. Rate, review and subscribe to this podcast on iTunes, Spotify, and more! Subscribe to our YouTube channel. Read Mission For America

Following the rollback of key climate provisions from the Inflation Reduction Act, the debate over America's energy future is increasingly contentious. The passage of the One Big Beautiful Bill Act has eliminated, or at least cobbled, many of the clean energy incentives that were centerpieces of Biden-era climate policy.  This week, climate policymakers, business leaders, investors, and advocates are converging in New York City for Climate Week. With so much happening and many questions around the pace of the energy transition, it's a crucial moment in US energy policy. So how are policymakers facing these challenges and working to accelerate clean energy deployment in a shifting political environment? What does pragmatic energy policy look like in an era of deep partisanship? And what should the policy response be to rising electricity demand in the US? This week, Jason Bordoff speaks to Congressman Sean Casten about the current state of clean energy deployment in the US. Congressman Casten represents Illinois's 6th congressional district and serves on both the House Financial Services Committee and the Joint Economic Committee. He's also vice chair of the Sustainable Energy and Environment Coalition. Before entering Congress, Rep. Casten was a clean energy entrepreneur and consultant, serving as CEO of Turbo Steam Corporation and as founding chairman of the Northeast CHP Initiative. Credits: Hosted by Jason Bordoff and Bill Loveless. Produced by Mary Catherine O'Connor, Caroline Pitman, and Kyu Lee. Engineering by Gregory Vilfranc.  

Ready to take control of your retirement? Start your Retirement TEAM Action Plan at ARHQ.com or call 419-794-3030 to speak with a retirement planning specialist today! Medicare Annual Enrollment Period: Are You Ready? (Oct 15 - Dec 7)In this episode, Scott Kerschner breaks down the upcoming changes to Medicare that could catch beneficiaries off guard. From premium hikes and Medigap policy shifts to the surprising role of AI in streamlining processes, we explore what’s evolving and why it matters. The conversation also highlights the Inflation Reduction Act’s ripple effects and the critical importance of staying informed during the annual election period. Whether you're a beneficiary or an advisor, this episode offers a grounded look at how to navigate the shifting Medicare landscape with clarity and confidence. About America's Retirement Headquarters: We are dedicated to helping retirees achieve the retirement they deserve. From crafting personalized retirement income strategies to providing a single location for all your retirement solutions, our goal is to guide you every step of the way. Let us help you navigate the complexities of retirement, so you can enjoy financial confidence and peace of mind. Visit Us: 1700 Woodlands Drive, Maumee, OH 43537 Call Us: 419-794-3030 Learn More: ARHQ.com See omnystudio.com/listener for privacy information.

The past few years have seen a seismic shift in energy and industrial policy in the United States. Under Biden, laws like the Inflation Reduction Act led to money pouring into clean energy manufacturing and deployment. The Trump administration has reversed course, cutting off incentives in instituting massive tariffs.  As a result, entire clean energy projects have been put on hold or even canceled. Workers who were counting on those projects now face an uncertain future. This situation forces tough questions for unions: Where do they go from here? Guests:  Roxanne Brown, Vice President at Large, United Steelworkers  Lee Anderson, Director of Governmental Affairs, Utility Workers Union of America Lara Skinner, Executive Director, Climate Jobs Institute, Cornell University Episode Highlights: 00:00 Intro 3:46 Roxanne Brown on the origins of USW's environmental advocacy 5:50 Roxanne Brown on the effects of climate workers are feeling today 14:25 Roxanne Brown on how energy policy has affected USW members  18:45 Roxanne Brown on climate messaging within USW 24:16 Lee Anderson on the jobs of utility workers 25:41 Lee Anderson on how climate has affected the safety of workers 30:54 Lee Anderson on UWUA's input on current federal policy 40:15 Lara Skinner on what sparked a worker centered agenda on climate policy 42:36 Lara Skinner on the ups and downs of Climate Jobs New York's work 48:57 Lara Skinner on creating state based coalitions For show notes and related links, visit ClimateOne.org. *** Support Climate One by going ad-free! By subscribing to Climate One on Patreon, you'll receive exclusive access to all future episodes free of ads, opportunities to connect with fellow Climate One listeners, and access to the Climate One Discord. Sign up today. Ad sales by Multitude. Contact them for ad inquiries at multitude.productions/ads Learn more about your ad choices. Visit megaphone.fm/adchoices

The past few years have seen a seismic shift in energy and industrial policy in the United States. Under Biden, laws like the Inflation Reduction Act led to money pouring into clean energy manufacturing and deployment. The Trump administration has reversed course, cutting off incentives in instituting massive tariffs.  As a result, entire clean energy projects have been put on hold or even canceled. Workers who were counting on those projects now face an uncertain future. This situation forces tough questions for unions: Where do they go from here? Guests:  Roxanne Brown, Vice President at Large, United Steelworkers  Lee Anderson, Director of Governmental Affairs, Utility Workers Union of America Lara Skinner, Executive Director, Climate Jobs Institute, Cornell University Episode Highlights: 00:00 Intro 3:46 Roxanne Brown on the origins of USW's environmental advocacy 5:50 Roxanne Brown on the effects of climate workers are feeling today 14:25 Roxanne Brown on how energy policy has affected USW members  18:45 Roxanne Brown on climate messaging within USW 24:16 Lee Anderson on the jobs of utility workers 25:41 Lee Anderson on how climate has affected the safety of workers 30:54 Lee Anderson on UWUA's input on current federal policy 40:15 Lara Skinner on what sparked a worker centered agenda on climate policy 42:36 Lara Skinner on the ups and downs of Climate Jobs New York's work 48:57 Lara Skinner on creating state based coalitions For show notes and related links, visit ⁠ClimateOne.org⁠. *** Support Climate One by going ad-free! By subscribing to Climate One on ⁠Patreon⁠, you'll receive exclusive access to all future episodes free of ads, opportunities to connect with fellow Climate One listeners, and access to the Climate One Discord. ⁠Sign up today⁠. Ad sales by ⁠Multitude⁠. Contact them for ad inquiries at ⁠multitude.productions/ads⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this eye-opening episode, Dr. Lindsey Elmore exposes the chaos unfolding in the UK as Mounjaro (weight loss/diabetes medication) prices skyrocket 170% overnight—jumping from £92 to £330 per month. Discover how Eli Lilly's "European price matching" triggered panic buying, crashed pharmacy websites, and left patients spending over £1,000 to stockpile medications. Lindsey examines the real-world impact, even in the U.S.: supply shortages, hoarding behaviors, and the unfair advantage given to those who can afford to bulk-buy versus patients with genuine medical needs. A must-listen for understanding how arbitrary pharmaceutical pricing decisions affect real people's access to life-sustaining medications.Main Topic Introduction00:00-00:30: Discussion focuses on Mounjaro (weight loss/diabetes medication) pricing crisis in the UKThe Price Hike00:37-01:13: Massive 170% price increase starting September 1st, 2025Current price: £92/monthNew price: £330/month (up from planned £122/month)01:25-01:41: Eli Lilly justifies increase as "adjusting prices to match the rest of Europe"Pharmacy Response00:37 & 01:41-02:01: UK's largest online pharmacy "Pharmacy2U" freezes prices, then stops sales entirelyPanic Buying Crisis02:09-02:34: Patients stockpiling medications before price hikes02:22: Pharmacies offering 3, 6, or 9-month bundles02:44-02:59: Real examples: patients buying 7-8 pens, spending over £1,000 in panic purchases04:35: Pharmacy websites crashing from demandSupply Chain Impact02:59-03:24: Hoarding strains supply chains and prevents access for patients who truly need the medication03:24-03:44: Medical experts urge against hoarding injectable medications at homeCore Issues Identified03:51-04:12: Access and fairness concerns - distinguishing between medical necessity vs. cosmetic use05:37-05:57: Drug prices change "for no reason at all" with no patient input06:08-06:27: Need to prioritize patients who medically need medications over those who can afford to stockpileSolutions Proposed04:59-05:27: Work with legislators through existing Inflation Reduction Act framework06:27-06:55: Legislative action needed to control "absurd" arbitrary drug pricing, especially for life-sustaining medicationsEpisode Conclusion07:06-07:14: Show closing: encouraging wise health decisionsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-lindsey-elmore-show--5952903/support.

Alan Tonelson. Mexico Considers Tariffs on China Amidst US Pressure and Manufacturing Shifts. Mexico considers tariffs on China to protect local industry, aligning with Trump 2.0's North American trade strategy. China's export-driven model faces global pushback. US manufacturing capital spending rises despite job uncertainty. A Hyundai plant in Georgia controversially employed South Koreans lacking proper papers, challenging the Inflation Reduction Act's American job goals. 1911 MEXICO CITY

CONTINUED  Alan Tonelson. Mexico Considers Tariffs on China Amidst US Pressure and Manufacturing Shifts. Mexico considers tariffs on China to protect local industry, aligning with Trump 2.0's North American trade strategy. China's export-driven model faces global pushback. US manufacturing capital spending rises despite job uncertainty. A Hyundai plant in Georgia controversially employed South Koreans lacking proper papers, challenging the Inflation Reduction Act's American job goals. 1647

SHOW SCHEDULE 9-8-25 CBS EYE ON THE WORLD WITH JOHN BATCHELOR GOOD EVENING: The show begins in Yemen, asking what is to be done with the pirate Houthis? 1993 YEMEN FIRST HOUR 9-915 Bridget Toomey, Bill Raggio. Israel Strikes Houthis in Yemen Amidst Renewed Conflict and US Policy Flaws. Israel has intensified strikes against Houthis in Yemen, assassinating 12 government members in August. A previous USdeal enabling continued Houthi attacks on Israel is criticized. The Iranian proxy retaliated with new attacks and detained UN personnel. International response to Red Sea aggression is stalled, complicated by the Israeli conflict and geopolitical interests.915-930 CONTINUED Bridget Toomey, Bill Raggio. Israel Strikes Houthis in Yemen Amidst Renewed Conflict and US Policy Flaws. Israel has intensified strikes against Houthis in Yemen, assassinating 12 government members in August. A previous USdeal enabling continued Houthi attacks on Israel is criticized. The Iranian proxy retaliated with new attacks and detained UN personnel. International response to Red Sea aggression is stalled, complicated by the Israeli conflict and geopolitical interests.930-945 David Daoud. Jerusalem Terror Attack Highlights Persistent West Bank Threats and Gaza War Dynamics. A Jerusalem bus attack by West Bank Palestinians killed six, reflecting persistent terror and security gaps. Israel'sGaza City incursion proceeds slowly, impacted by depleted resources and international opposition. Israel may use the invasion threat for Hamas concessions. President Trump supports Israel's operations but urges the war's end, impacting Israel's image.945-1000 CONTINUED David Daoud. Jerusalem Terror Attack Highlights Persistent West Bank Threats and Gaza War Dynamics. A Jerusalem bus attack by West Bank Palestinians killed six, reflecting persistent terror and security gaps. Israel'sGaza City incursion proceeds slowly, impacted by depleted resources and international opposition. Israel may use the invasion threat for Hamas concessions. President Trump supports Israel's operations but urges the war's end, impacting Israel's image. SECOND HOUR 10-1015 Malcolm Hoenlein. Jerusalem Terror Attack and Gaza Offensive Amidst Global Geopolitical Shifts.A Jerusalem bus terror attack killed six; Gaza offensive targets Hamas infrastructure amidst propaganda. UAEcondemned the attack. France's government fell, impacting Macron's Palestinian state push. Iraq probes Iranian oil smuggling, and Iran established UK sleeper cells. A controversial anti-American Detroit conference, with Congresswoman Tlaib, occurred. Public support for Israel remains strong. 1015-1030 CONTINUED  Malcolm Hoenlein. Jerusalem Terror Attack and Gaza Offensive Amidst Global Geopolitical Shifts. A Jerusalem bus terror attack killed six; Gaza offensive targets Hamas infrastructure amidst propaganda. UAEcondemned the attack. France's government fell, impacting Macron's Palestinian state push. Iraq probes Iranian oil smuggling, and Iran established UK sleeper cells. A controversial anti-American Detroit conference, with Congresswoman Tlaib, occurred. Public support for Israel remains strong.1030-1045 JANATYN SAYEH. Israel Amplifies Anti-Regime Messaging in Iran Amidst Shadow War and Rearmament Concerns. Iran anticipates war as Israel targets nuclear sites and supports the Iranian opposition, projecting a prosperous post-regime future. Tehran now sees Israel, not US, as the primary regime-change threat. China provides economic support, but Iran's proxies face rearmament challenges. Uncertainty on Iran's nuclear material and enrichment capacity fuels potential Israeli attacks. 1045-1100 CONTINUED JANATYN SAYEH. Israel Amplifies Anti-Regime Messaging in Iran Amidst Shadow War and Rearmament Concerns. Iran anticipates war as Israel targets nuclear sites and supports the Iranian opposition, projecting a prosperous post-regime future. Tehran now sees Israel, not US, as the primary regime-change threat. China provides economic support, but Iran's proxies face rearmament challenges. Uncertainty on Iran's nuclear material and enrichment capacity fuels potential Israeli attacks. THIRD HOUR 1100-1115 John HardIe. Russia Intensifies Ukraine Barrage; Trump Faces Pressure for Stronger Sanctions. Russia launched a massive drone and missile attack on Ukraine, signaling Putin's refusal to negotiate. President Trumpfaces pressure to implement tougher sanctions on Russian oil revenue. Ukraine faces infantry shortages and porous lines but is improving air defenses. Russian advances are slow, struggling to exploit Ukrainian vulnerabilities on the battlefield.1115-1130 CONTINUED  John HardIe. Russia Intensifies Ukraine Barrage; Trump Faces Pressure for Stronger Sanctions. Russia launched a massive drone and missile attack on Ukraine, signaling Putin's refusal to negotiate. President Trumpfaces pressure to implement tougher sanctions on Russian oil revenue. Ukraine faces infantry shortages and porous lines but is improving air defenses. Russian advances are slow, struggling to exploit Ukrainian vulnerabilities on the battlefield. 1130-1145 Ernesto Araújo, Alejandro Peña Esclusa. US Escalates Anti-Drug Operations in Venezuela; Brazil Shows Support for Trump Against Lula. President Trump enacted a military doctrine targeting Venezuelan drug cartels, including a boat strike, with Venezuelans hoping for liberation from Maduro. In Brazil, public support for Trump and Bolsonaro signals desire for US alliance against Lula's government. Trump threatens tariffs if Bolsonaro is jailed.1145-1200 CONTINUED Ernesto Araújo, Alejandro Peña Esclusa. US Escalates Anti-Drug Operations in Venezuela; Brazil Shows Support for Trump Against Lula. President Trump enacted a military doctrine targeting Venezuelan drug cartels, including a boat strike, with Venezuelans hoping for liberation from Maduro. In Brazil, public support for Trump and Bolsonaro signals desire for US alliance against Lula's government. Trump threatens tariffs if Bolsonaro is jailed. FOURTH HOUR 12-1215  Alan Tonelson. Mexico Considers Tariffs on China Amidst US Pressure and Manufacturing Shifts. Mexico considers tariffs on China to protect local industry, aligning with Trump 2.0's North American trade strategy. China's export-driven model faces global pushback. US manufacturing capital spending rises despite job uncertainty. A Hyundai plant in Georgia controversially employed South Koreans lacking proper papers, challenging the Inflation Reduction Act's American job goals.1215-1230 CONTINUED  Alan Tonelson. Mexico Considers Tariffs on China Amidst US Pressure and Manufacturing Shifts. Mexico considers tariffs on China to protect local industry, aligning with Trump 2.0's North American trade strategy. China's export-driven model faces global pushback. US manufacturing capital spending rises despite job uncertainty. A Hyundai plant in Georgia controversially employed South Koreans lacking proper papers, challenging the Inflation Reduction Act's American job goals.1230-1245 Kelly Currie. Indonesia Navigates Geopolitical Tensions and Domestic Instability Amidst Cabinet Shuffle. Indonesian President Prabowo attended a Chinese parade, balancing China's investment with other alliances amidst domestic protests. Indonesia grapples with persistent corruption, police brutality, and deep-seated societal tensions. A cabinet reshuffle, replacing Finance Minister Sri Mulyani Indrawati, risks economic instability despite growth promises. Indonesia seeks US balance against China.1245-100 AM Michael Sobolik. China's Biowarfare Ambitions Threaten US Dominance and Global Health. China's Communist Party develops biowarfare, including ethnic-specific genetic attacks, to achieve strategic dominance over the US. China aims to divert US biotech innovation and control future vaccine distribution, leveraging lessons from COVID-19. US vaccine hesitancy and decreased investment in cutting-edge technology leave it dangerously exposed to future biothreats.

Trump’s One Big Beautiful Bill Act reorients U.S. energy policy, redefining its rivalry with China and the global transition. --- Once, climate and clean energy were common ground between the United States and China, most notably in the lead-up to the 2015 Paris Agreement. In the years since, cooperation has given way to competition. China has emerged as the global leader in clean energy manufacturing, while the U.S.—under the Biden administration—moved to catch up through the Inflation Reduction Act. Now, President Trump’s One Big Beautiful Bill Act has set a very different course. The law rolls back many clean energy incentives, puts new emphasis on fossil fuels and emerging technologies like advanced nuclear and certain hydrogen sources, and sharpens trade and supply chain tensions with China through expanded tariffs and Foreign Entity of Concern restrictions. What does this shift mean for U.S.–China relations, American competitiveness, and the global energy transition? Scott Moore, director of China programs and strategic initiatives at the University of Pennsylvania, joins Energy Policy Now to unpack the stakes. A leading expert on U.S.–China relations, Moore offers perspective on how Trump’s policies could reshape the balance of power between the world’s two largest economies. Scott Moore is Practice Professor of Political Science, and Director of China Programs and Strategic Initiatives, at the University of Pennsylvania. Related Content Climate Action in the Age of Great Power Rivalry: What Geopolitics Means for the Climate https://kleinmanenergy.upenn.edu/research/publications/climate-action-in-the-age-of-great-power-rivalry-what-geopolitics-means-for-the-climate/ Mitigating Climate Change Through Green Investments https://kleinmanenergy.upenn.edu/research/publications/mitigating-climate-change-through-green-investments/ Energy Policy Now is produced by The Kleinman Center for Energy Policy at the University of Pennsylvania. For all things energy policy, visit kleinmanenergy.upenn.edu.See omnystudio.com/listener for privacy information.

An Inflation Reduction Act subsidy for electric vehicles is being shut down by the Trump administration at the end of September, and automakers are preparing for sales of EVs to slow. Can this nascent industry survive?  Guest: ⁠Ryan Felton⁠, reporter covering the automotive industry for the Wall Street Journal Learn more about your ad choices. Visit megaphone.fm/adchoices

An Inflation Reduction Act subsidy for electric vehicles is being shut down by the Trump administration at the end of September, and automakers are preparing for sales of EVs to slow. Can this nascent industry survive?  Guest: Ryan Felton, reporter covering the automotive industry for the Wall Street Journal Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

An Inflation Reduction Act subsidy for electric vehicles is being shut down by the Trump administration at the end of September, and automakers are preparing for sales of EVs to slow. Can this nascent industry survive?  Guest: Ryan Felton, reporter covering the automotive industry for the Wall Street Journal Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

An Inflation Reduction Act subsidy for electric vehicles is being shut down by the Trump administration at the end of September, and automakers are preparing for sales of EVs to slow. Can this nascent industry survive?  Guest: ⁠Ryan Felton⁠, reporter covering the automotive industry for the Wall Street Journal Learn more about your ad choices. Visit megaphone.fm/adchoices

An Inflation Reduction Act subsidy for electric vehicles is being shut down by the Trump administration at the end of September, and automakers are preparing for sales of EVs to slow. Can this nascent industry survive?  Guest: Ryan Felton, reporter covering the automotive industry for the Wall Street Journal Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

An Inflation Reduction Act subsidy for electric vehicles is being shut down by the Trump administration at the end of September, and automakers are preparing for sales of EVs to slow. Can this nascent industry survive?  Guest: Ryan Felton, reporter covering the automotive industry for the Wall Street Journal Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

“Storage Was Never Just an Add-On”What if we've been thinking too small about batteries?In this rebroadcast from RE+, Kiran Kumaraswamy, former VP of Growth at Fluence, makes a bold case for reimagining energy storage—not just as a renewable add-on, but as a foundational tool for grid transformation. Kiran breaks down how the energy storage sector evolved from supporting solar to replacing gas peakers, enhancing transmission, and becoming central to resiliency planning. Long before the IRA supercharged the market, he was urging utilities and regulators to rethink what batteries could do—and now, we're seeing those ideas implemented at scale.From the Inflation Reduction Act's massive market tailwinds to the rise of virtual transmission, this conversation is loaded with strategy, foresight, and tactical insight for storage developers, grid planners, and policy leaders alike.Expect to learn:

Join Cato's Alex Nowrasteh and Travis Fisher as they unpack a pivotal moment in climate policy reform. The duo explores Fisher's tenure at the Department of Energy and the groundbreaking report that could reshape the discourse on greenhouse gases.Travis Fisher, “Why I Helped Organize the Department of Energy's Climate Report,” Cato at Liberty (August 6, 2025)Travis Fisher and Joshua Loucks, “The Budgetary Cost of the Inflation Reduction Act's Energy Subsidies,” Policy Analysis (March 11, 2025)Patrick J. Michaels, “Cato Releases Report on EPA Endangerment Finding,” News Releases (October 31, 2012) Hosted on Acast. See acast.com/privacy for more information.

The rollback of the Inflation Reduction Act through the One Big Beautiful Bill Act has reshaped America's climate and energy landscape by cutting tax incentives for wind and solar power and electric vehicles while maintaining some federal support for sources like nuclear reactors and geothermal plants.  While there is some uncertainty about how those policy changes will play out, there are even broader questions about what this all means for the Republican Party's energy policy agenda and approach to climate change.  So where is the party headed and what could bipartisan cooperation on energy policy look like in today's Washington? Can Republicans and Democrats still find common ground on issues like climate adaptation, energy security, and permitting reform? And what is shaping the Republican Party's approach to energy policy?  This week, Jason talks to Carlos Curbelo about the current state of Republican thinking on energy and climate policy. Carlos is a former member of the U.S. House of Representatives. He served Florida's 26th congressional district from 2015 to 2019. During his time in Congress, Carlos was a leading Republican voice on climate policy, co-founding and co-chairing the bipartisan Climate Solutions Caucus. After leaving Congress, Carlos served as a distinguished visiting fellow at the Center for Global Energy Policy. He also co-founded Vocero, a communications and strategic consulting firm based in South Florida. Credits: Hosted by Jason Bordoff and Bill Loveless. Produced by Mary Catherine O'Connor, Caroline Pitman, and Kyu Lee. Engineering by Gregory Vilfranc.  

In the latest episode of the Health Matters podcast, former Food and Drug Administration Commissioner Scott Gottlieb joins WPP’s Wendy Lund, GCI Health’s Ryan Kuresman and Burson’s Judy Stecker to discuss the forces reshaping U.S. health policy. Gottlieb warns that while new laws such as the Inflation Reduction Act may lower government spending on drugs, consumers are unlikely to see significant relief at the pharmacy counter. Insurers’ tighter formularies and higher cost-sharing requirements, he said, could continue to drive affordability challenges for patients. The discussion also covers the future of direct-to-consumer advertising, FDA’s role in combating health misinformation and the promise of cell and gene therapies. Gottlieb shares both caution and optimism — noting the risk of consumer frustration if policy changes fail to deliver savings, while pointing to breakthroughs that are transforming treatment and outcomes. To hear his full take on the challenges and opportunities facing health care leaders, listen to the full Health Matters episode.See omnystudio.com/listener for privacy information.

Dental & Vision Plans.  Dental coverage explained.  July 4th and USA.  Inflation Reduction Act.  Rising Deductibles.  Co-pay VS Co-Insurance.  Lobbyists and their role.  United Healthcare Fraud Case.

The Inflation Reduction Act introduced a broad range of renewable energy tax credits. Now, the One Big Beautiful Bill Act (OB3) has reshaped these incentives with new compliance requirements, shifting timelines, and selective phaseouts. In this podcast, we cover what's changed, what's stayed the same, and the implications for companies navigating the evolving renewable energy tax credit landscape.In this episode, we discuss:1:51 – Significant changes to energy credits from OB39:28 – Energy credit modifications, early sunsets, and what remains unchanged14:07 – New guidance for wind and solar industry clean electricity credits21:14 – Immediate actions for companies to maximize opportunities under OB3Looking for the latest developments in sustainability reporting? Follow this podcast on your favorite podcast app and subscribe to our weekly newsletter to stay in the loop for the latest thought leadership on sustainability standards.About our guestJennifer Bernardini is a managing director in PwC's Washington National Tax practice. She has over 20 years of experience implementing federal energy tax incentives that support the development of renewable energy and the climate transition.About our guest hostGuest host Diana Stoltzfus is a partner in the National Office who helps to shape PwC's perspectives on regulatory matters, responses to rulemakings and policy development, and implementation related to significant new rules and regulations. Prior to rejoining PwC, Diana was the Deputy Chief Accountant in the Office of the Chief Accountant (OCA) at the SEC where she led the activities of the OCA's Professional Practices Group.Transcripts available upon request for individuals who may need a disability-related accommodation. Please send requests to us_podcast@pwc.comDid you enjoy this episode? Text us your thoughts and be sure to include the episode name.

Three years ago this month, the Inflation Reduction Act passed, marking the largest investment in climate policy in U.S. history. It included over $300 billion to address global warming and was expected to unlock nearly $3 trillion in private investment by 2032. But then came Donald Trump.  Over the last eight months, the Trump administration has worked to dismantle much of that progress, including withholding funds, canceling loans and grants, and working with Congress to roll back tax credits. For those working in climate tech, it's been a pretty dark time.  But U.S. Sen. John Hickenlooper of Colorado, one of the lawmakers behind the IRA, says he's surprisingly optimistic about future policy wins despite White House opposition to climate and clean tech.  In this episode, Lara talks with Sen. Hickenlooper about passing the landmark climate law and protecting it, his ideas for building a bipartisan coalition for permitting reform, and why he's actually hopeful eight months into Trump's second term. Credits: Hosted by Lara Pierpoint. Produced by Erin Hardick. Edited by Anne Bailey and Stephen Lacey. Original music and engineering by Sean Marquand. Stephen Lacey is executive editor. The Green Blueprint is a co-production of Latitude Media and Trellis Climate. Subscribe on Apple, Spotify, or anywhere you get podcasts. For more reporting on the companies featured in this podcast, subscribe to Latitude Media's newsletter.

“Energy efficiency…is doing more, using less. The megawatt not used is the cheapest megawatt and there's so many things, either by using technology, old technology like insulation or digitalization, that allows us to really stretch what we can get out every single megawat, a kilowatt electron that we use. And so that's what we're talking about. If we had the kind of massive adoption that we need, we could get to a big 40% reduction.” Paula Glover on Electric Ladies Podcast With the Energy Star program and other energy efficiency programs under attack and misunderstood, we decided to revisit this enlightening discussion with Paula Glover, CEO of the Alliance To Save Energy and Electric Ladies host Joan Michelson. She also shares insightful career advice. The International Energy Agency (IEA) said energy efficiency should be one of the cornerstones of reducing our carbon emissions to address global warming – and incentives in the Inflation Reduction Act and Infrastructure Investment Act were designed to do just that. But now those are being cut or curtailed. How can energy efficiency really make a difference? Listen to this episode. You'll hear about: What the Alliance To Save Energy is and who its members are, the impact they have. What energy efficiency really is – and is not. How you can identify and tap the savings to increase the energy efficiency of your home, business, school or community. What the Roadmap for a Just Energy Transition is and how it works. Plus, insightful career advice, such as… “One would be, relationships matter, and you should be feeding into them as much as you want to get out of it. So, it's not about who….Number two, which is that as much as you're looking for a mentor, you should also be a mentor. And that mentorship is not just, I'm at 15 years and so I mentor someone who's at five. But if you really nurture relationship, you could be at 15 years mentoring someone who's at 25 years, right? You have something to contribute….There is so much that we have to contribute at every stage of our career. I think taking the opportunity to do that leads to other opportunities that you may never have known about.” Paula Glover on Electric Ladies Podcast Read Joan's Forbes articles here. You'll also like: Congresswoman Chrissy Houlahan (D-PA), on the politics of energy and infrastructure Doreen Harris, President and CEO of NYSERDA, on how New York is leading the way to the clean energy future. Autum Huskins, Hitachi Zosen Inova, turning waste into energy (and wine) Marit Brommer, Ph.D., International Geothermal Association, how geothermal is a dependable energy source Claire Seaborn, former Chief of Staff to Canada's Minister of Energy and Natural Resources on what the U.S. can learn from Canada's energy policies Subscribe to our newsletter to receive our podcasts, blog, events and special coaching offers.. Thanks for subscribing on Apple Podcasts or iHeartRadio and leaving us a review! Follow us on Twitter @joanmichelson

The Rich Zeoli Show- Hour 3: 5:05pm- Bill D'Agostino—Senior Research Analyst at Media Research Center—joins The Rich Zeoli Show to break down some of the best (and worst) moments from corporate media and Democrats. PLUS, NewsBusters celebrates its 20th birthday with a compilation of the craziest clips from the last two decades! 5:30pm- While speaking with Miranda Devine, EPA Director Lee Zeldin revealed that since taking office he has unearthed examples of billions of dollars from the Inflation Reduction Act being sent to several NGOs with conflicting interests/ties to the Obama and Biden Administrations.

The Rich Zeoli Show- Full Show (08/20/2025): 3:05pm- California Governor Gavin Newsom is now mimicking President Donald Trump's social media style. For example, after Dana Perino critiqued his strategy to garner attention, Newsom's press office posted to X: “DANA ‘DING DONG' PERINO (NEVER HEARD OF HER UNTIL TODAY!) IS MELTING DOWN BECAUSE OF ME, GAVIN C. NEWSOM! FOX HATES THAT I AM AMERICA'S MOST FAVORITE GOVERNOR (‘RATINGS KING') SAVING AMERICA—WHILE TRUMP CAN'T EVEN CONQUER THE ‘BIG' STAIRS ON AIR FORCE ONE ANYMORE!!! TRUMP HAS “LOST HIS STEP” AND FOX IS LOSING IT BECAUSE WHEN I TYPE, AMERICA NOW WINS!!! THANK YOU FOR YOUR ATTENTION TO THIS MATTER.” While outlets like Pod Save America and Politico praise the posts, are they going to help win Newsom any support in 2028? Unlikely. 3:30pm- Rich is taping at Fox News on Friday and is on vacation next week. And when he comes back, he'll be preempted for a Philadelphia Phillies broadcast—consequently, it is possible Rich will be able to break his own record for shortest radio show in 1210 WPHT history. His previous record was 13-minutes! 3:50pm- Manhattan Federal Judge Richard Berman has rejected the Justice Department's request to release grand jury testimony related to Jeffrey Epstein. 4:05pm- On Wednesday, Vice President JD Vance and Defense Secretary Pete Hegseth visited National Guard troops who were placed at Union Station in Washington, D.C. as part of the Trump Administration's efforts to reduce violent crime in the nation's capital. White House Deputy Chief of Staff Stephen Miller commented on protesters in opposition to the crime crackdown: "We're going to ignore these stupid white hippies that all need to go home and take a nap because they're all over 90 years old." 4:25pm- During a Wednesday Zoom conversation, Texas Representative Nicole Collier was informed that she was needed on the Texas House floor to participate in a vote on redistricting. Collier fled the state earlier this month in an attempt to deny the Texas House a quorum—effectively preventing a vote on redistricting and halting a vote on providing financial relief for families impacted by last month's devastating floods that killed more than 120 people. In response to Collier's forced departure from the Zoom meeting, Sen. Cory Booker screamed: “freaking outrageous!” 4:30pm- In response to Hurricane Erin, Governor Phil Murphy said: "I don't want to be the Amityville mayor from Jaws, but the fact of the matter is, I think going in the ocean for the next number of days is something you got to avoid.” 4:45pm- Rep. Eric Swalwell posted a video of himself buying groceries. At least he's buying cheese now instead of cutting it on television! Matt plays his favorite audio: Swalwell's gassy appearance on MSNBC with Chris Matthews from 2019. 5:05pm- Bill D'Agostino—Senior Research Analyst at Media Research Center—joins The Rich Zeoli Show to break down some of the best (and worst) moments from corporate media and Democrats. PLUS, NewsBusters celebrates its 20th birthday with a compilation of the craziest clips from the last two decades! 5:30pm- While speaking with Miranda Devine, EPA Director Lee Zeldin revealed that since taking office he has unearthed examples of billions of dollars from the Inflation Reduction Act being sent to several NGOs with conflicting interests/ties to the Obama and Biden Administrations. 6:00pm- Judge Announces Wrong Verdict in Murder Case: A Fulton County jury acquitted Alton Oliver of murdering off-duty Deputy James Thomas, agreeing he acted out of fear after repeated late-night advances and confrontations. In court, however, Judge Henry M. Newkirk mistakenly read the verdict as “guilty” before being corrected that the official verdict form declared Oliver “not guilty” on all counts. 6:10pm- Rhode Island Assistant Attorney General Devon Flanagan (a Democrat appointee) was arrested after refusing to leave a restaurant. In the viral video, Flanagan—who appears to be intoxic ...

Title: How You Can Win Trump's Tariff War  Summary: The video hosted by Seth Bradley discusses the potential economic implications of President Trump's aggressive tariff policies and how they might present unique opportunities for wealth building in America amidst global economic upheaval. Bradley explains that tariffs—essentially taxes on imports—are economic tools that can protect domestic industries but also lead to broader economic challenges, particularly if not applied thoughtfully. He outlines the dynamics of Trump's tariff strategy, including a systematic and reciprocal approach to trade that could reshape relationships with various countries.   Seth Bradley emphasizes that while the stock market is experiencing volatility and media outlets are reacting negatively, there are underlying opportunities that savvy investors should seize. He advocates for a focus on U.S. manufacturing and infrastructure, energy independence, and advancements in AI and automation as key areas for investment. The video posits that although immediate challenges like inflation and retaliation from trade partners are likely, the long-term outlook sees a potential reshoring of American industry, a reemergence of economic sovereignty, and ultimately an empowered U.S. economy. Links to Watch and Subscribe: https://www.youtube.com/watch?v=DgWxz_V0lPk&list=PLSfheWyV7beFqERLX4ebBUJ4SmzmF6z8e&index=2 Bullet Point Highlights: Market Volatility: The stock market sees a significant downturn as tariffs take effect, presenting both challenges and opportunities. Tariff Strategy: Trump's tariffs are described as calculated economic warfare, designed to compel countries to negotiate trade terms. Manufacturing Reshoring: The video advocates for investing in U.S.-based manufacturing as companies look to bring jobs back onshore. Energy Independence: Emerging opportunities in U.S. energy production are highlighted amid tariffs hurting foreign oil imports. AI and Automation: The potential for AI-driven solutions to replace expensive offshore labor costs is discussed as a strategic investment avenue. Investment Strategies: Three key strategies are proposed for capitalizing on the unique economic landscape: investing in infrastructure, energy, and AI technologies. Vision for the Future: The potential long-term benefits of Trump's tariff policies are framed as a chance to reset trade imbalances and promote U.S. economic strength. Transcript: (Seth Bradley) Trump just broke the global economy and it might be the best thing to happen to America in decades. The stock market is crashing. China, Mexico, Canada, they're retaliating. The mainstream media is melting down. But the truth, if you understand what's really going on, this might be the single greatest opportunity of the decade to build wealth. So, let's break it down. No fluff, just facts. What's up, big brains? Welcome back to Raise the Bar, where I simplify complex money, legal, and political moves so you   can make power plays in real time. I'm Seth Bradley, securities attorney, founder, and investor, and I quit a multiple six-f figureure big law job to pursue entrepreneurship and a life without limits. Today, I'm giving you the truth about tariffs, Trump's Liberation Day, and how to turn this global shakeup into your personal leverage point. All right, let's get it. Let's start out with the basics. So, what exactly is a tariff? At its core, a tariff is a tax on imports. That's right. It is a tax. When a foreign   company sells goods into the US, the government slaps on a tax, usually a percentage of the total value. So, if a car from Germany costs 50k and there's a 10% tariff, then that car now costs $55,000 to bring into the US. So, who pays the tariff? Well, it's US importers, not the foreign shippers. And yes, it trickles down to you, the consumer, right here in the US. But tariffs aren't just taxes. They're economic weapons. And right now, Trump's using them with either surgical precision or as a nuclear bomb,   depending on how you look at it. All right. To know where you're going to go, you have to know where you come from. Tariffs go way back in American history. It's not anything new. And in fact, before the IRS, tariffs were how we paid for the entire federal government, rather than through, let's say, income taxes, property, capital gains taxes, and all these other taxes that we all just know and love today. Tariffs haven't always resulted in good or bad for the US. It's a mixed bag. Alexander Hamilton pushed for tariffs to protect   US industry. Success, yes. Abraham Lincoln used them to industrialize the North during the Civil War. Success, yes. But in the 1930s, the Smooth Holly Tariff Act backfired hard, triggering a trade war that deepened the Great Depression. So, not always successful. Tariffs can protect jobs and industries, but if they're too extreme or poorly timed, they can tank the economy. So, the key is strategy. And whether or not you believe in Trump, he's playing chess here, not checkers. Something you never   used to associate with Trump is humble, but he has come a long way and is humble enough to at least have some of the greatest economic minds in his corner. So, they have a business-minded mentality, and that's exactly what this is. We need to stop treating the government like it's aing goodwill. It's not here to give you for free, and it's certainly not here to take what's yours. It's here to work for you, for what the people want, and decide through a democratic process what to do. Once upon a time, we literally became a   country because we wanted independence, self-sufficiency, and freedom. We chose to break free from overt taxation, oppression, control, regulation, and government oversight. What's happening in 2025? In case you missed it, let's get caught up right now. Trump has declared Liberation Day and followed up with the most aggressive global tariff policy in modern history. A minimum of 10% tariffs on every import into the US, up to 60% tariffs on China. That changes every single day though. Reciprocal   tariffs on all countries. If a country charges us 25%, we charge them 25% back. But that's not exactly true. And we'll get into more of that later. Canada and Mexico not exempt. This isn't just about China. It's about a full global reset. So the kicker is formula based. Trump's trade team built a publicly disclosed algorithm that adjusts tariff rates based on countries how countries treat the US exports. It's dynamic. is constantly changing. It updates monthly. This isn't random. It's calculated   economic warfare. All right, next. Now that it's in effect, what's happening? Well, you're seeing it. Wall Street is panicking. S&P 500 is down 14% in the first two weeks. Tech stocks are plummeting. Elon Musk just posted on X that supply chain realignment is overdue and this pain is necessary. Mexico is negotiating. Canada's threatening retaliation, but also showing signs of blinking. China, they're digging the toes in, but there's exports that are suffering. You just won't hear all this stuff on CNBC, but you know, many of   these global players are coming to the table. Tariffs are doing exactly what they're designed to do. Force negotiation, good or bad. Trump's move is forcing every country to rethink dependence on the US consumer. And not just that, it's forcing us to rethink how we depend on them. All right, let's set the record straight on a few of these common things that are floating around here. One, tariffs only hurt the other country. That's totally wrong. US businesses and consumers feel the sting, and we will. We are, at least   at first. Sometimes you're going to hear this is just economic nationalism. But that's also wrong. This is about strategic leverage, not about isolating us. Third, it's inflationary in the short term. This is true. But if local supply chains relocize, prices stabilize and strengthen the domestic economy and we'll be good to go. But right now, we're feeling it. Next, tariffs can bring manufacturing back. This is true. Maybe, and we're already seeing US factories reannounced, reopenings in Michigan, Ohio, Pennsylvania, places   like that. And we've seen trillions of dollars of investment promises rolling in already. But if this steers us into a deep recession, companies won't have the resources or confidence to build. All right. So, what's my prediction? And some of these aren't even predictions cuz they're happening right now. Are risks, short-term inflation, price increases, stock market volatility, retaliation from trade partners. These things are already happening. So, they're probably just going to escalate for the near future.   But the potential upsides, reshoring of manufacturing, massive supply chain independence, huge massive negotiation leverage for better and at the very least equal trade terms. Stronger US dollars, capital fleas, unstable markets abroad. Those are all massive positives, but they're not going to happen overnight. So, what's my prediction? short-term pain, long-term economic sovereignty, but we're entering a serious rebalancing period, and the US is reasserting its economic power. And while it hurts now, this could finally   reset the broken trade game that's been bleeding our economy dry for decades and would eventually take us down. All right, so what do we do about it? We need to capitalize. So, what are the three smartest ways to capitalize on Trump's 2025 tariffs? There are lots of unknowns and unpredictability in business. But one thing is always true. When there's panic in the streets, there is massive opportunity somewhere and there's going to be wealth transfer. For those with cool heads, fortitude, and discipline, we can win. So, what am I   doing? And what can you do to capitalize on all of this unpredictability? All right. Strategy number one, invest in US manufacturing and infrastructure. Tariffs equal a return to Americanmade. Full stop. Trump's reciprocal tariffs aren't just economic sanctions. They're a forced reshoring event here in the US. Global trade is breaking. Supply chains are rerouting. Countries like China, Mexico, and Canada, they're scrambling to adjust. And meanwhile, America is rebuilding. This is your moment to build   wealth while the rest of the market panics. So, how do we actually do this? Play number one, invest passively in the U in industrial and infrastructure projects. Tap into private equity funds, syndications, or REIT alternatives that focus on, of course, manufacturing facilities, US-based supply chain logistics, cold storage, and warehouse assets, transportation, freight infrastructure, that stuff works, too. These funds are just pouring into the reshoring initiatives, not just from the government, but from Fortune 500   companies rethinking their risk exposure. Play number two for my capital raisers out there. Raise capital for experienced sponsors in the same space. If you're not the operator, but you've got a network, become a capital aggregator. Use SPVS or fund of funds models like TriVest to compliantly pull investor capital into high quality US industrial and infrastructure deals. Bring your network along. Bring limited partners into deals with better terms, higher leverage, and strategic upside. Focus on experienced sponsors. Of   course, do your due diligence. Make sure they have a track record in industrial real estate or again critical infrastructure. All right, play number three. If you have the resources, buy directly. Also got to have the knowhow, right? Focus on manufacturing assets, warehouses near growing ports, logistics hubs, things like that. Make sure you have a boots on the ground partner if it's not you in that local market. Think markets like Columbus, Kansas City. These cities are turning into many powerhouses as global shipping patterns   shift inland. Bonus play, buy dirt where the roads are going. Right? So, if you're into residential and you don't know anything about industrial and you're not comfortable with it, think about residential and mixed juice land near inland ports, new highways, industrial corridors, growth zones, things like that. These plays won't necessarily cash flow day one, but they will appreciate like crazy over the next 3 to 5 years as that infrastructure is finally built out. Strategy number two, energy independence investing. If   manufacturing is the body, energy is the blood, where are you going to power this thing from? Trump's tariffs are slamming foreign oil and renewables equipment. And that gives domestic US producers, especially in oil and gas and renewables such as batteries, an unmatched advantage. And with the world watching this tariff war unfold, there's one thing everyone agrees on. Energy is national security right now. So what do you do? Play number one, invest passively, of course, in US energy assets, oil and gas royalties, own a   slice of production without the drilling risk. You have to dig deep into those documents and see what you're getting yourself into. There's a lot of different oil and gas funds that are structured in different ways and have different tax incentives versus cash flow. So, make sure you dig deep into that. Also look at battery manufacturers like Stack Rack Battery, especially US-based ones, solar developers, those leveraging domestic supply chains. Look for funds and startups focused on energy independence, not just ESG headlines.   Real world example, I had mentioned StackRrack battery. I co-founded StackRrack, a US-based modular battery company. And we're not just producing batteries, we're part of the national grid modernized push. Our battery systems are designed, they're assembled, and they're shipped right here in the US. We're ULcertified, scalable, and recession resistant. And tariffs just gave us a built-in mode. This is exactly what happens when policy meets opportunity. You just have to open your eyes and find those right opportunities.   And a bonus here, tax credit tailwinds. The US is still offering massive tax credits under the Inflation Reduction Act, for now at least. Pair that with import based price increases and you've got a once in a decade profit window. And building on that, what's your capital aggregator play? If you don't want to operate, partner with fund managers or sponsors deploying capital into these sectors, be the legal, the capital raising or the strategic partner in high demand governmentbacked tariff fueled energy projects. My law firm,   Raise Law, can help you build any capital raising structure you can imagine. So feel free to reach out. All right, strategy number three, back or build AIdriven alternatives to offshore labor. Tariffs don't just hit goods, they hit services, too. Let me explain. Think about it. If China, Mexico, or Canada are now more expensive to work with because of reciprocal tariffs, that raises the cost of offshore labor. So, enter what's happening right now. AI, automation, US-based software. This is your moment to kill the middleman.   Reduce labor cost and automate what is already going to be offshored. This is your moment to kill the middleman. Reduce labor cost and automate what was once offshored in different countries. So here we go. Play number one. Build or invest in AI tools that replace outsource labor. Think about jobs like customer service, document review and data entry, uh logistics coordination, manufacturing floor labor, things like that. It's not sci-fi. The LLMs and the manufacturing robotics are ready today and the opportunity is right now. All   right, so step-by-step action plan. Identify high friction outsource tasks that just got more expensive. Right. Next, what's the capital aggregator play? partner with early stage AI founders or companies. Use your network expertise or capital raising jobs to make strategic investments or even try to leverage an advisory equity position or a role in a startup in these sectors. I've done it and feel free to reach out and I can tell you more about how I've done it. So, pro tip though, don't just invest in AI for the sake of it. Invest   in AI that displaces foreign labor. That's where the pressure is. That's where the real value will be. This is the moment most people will fear. We're in it right now and a few smart ones will capitalize. Tariffs are just the first shot in a major larger realignment. And if you're able to stay calm, not get caught up in all the political nonsense. This is a time where real wealth changes hands. Keep your mind clear, keep your eyes open, and if this breakdown helped you see the game clearer, smash that subscribe button,   drop a comment with your take on Trump's global economic strategy, and let me know, are you playing offense or defense? Keep your head in the game. Raise the bar, baby. Until next time, enjoy the journey. [Music] Links from the Show and Guest Info and Links: https://www.youtube.com/watch?v=DgWxz_V0lPk&list=PLSfheWyV7beFqERLX4ebBUJ4SmzmF6z8e&index=2 https://www.facebook.com/sethbradleyesq/posts/pfbid02RZL2XfebNjV7orN7Ze4Ue8z437ZobHSQoDoCZWwLNwG1VgsshZrRMSkyeGkydwZGl https://www.instagram.com/p/DIUN1PvTvgQ/ https://x.com/sethbradleyesq/status/1910758713683746925 https://www.linkedin.com/posts/sethbradleyesq_tariffs-trump2025-donaldtrump-activity-7316522747164086272-47ae?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAKVay0BMf-qnL2v6W-30PvVRZnCs0eCFQU https://x.com/sethbradleyesq https://www.youtube.com/@sethbradleyesq www.facebook.com/sethbradleyesq https://www.threads.com/@sethbradleyesq https://www.instagram.com/sethbradleyesq/ https://www.linkedin.com/in/sethbradleyesq/ https://passiveincomeattorney.com/seth-bradley/ https://www.biggerpockets.com/users/sethbradleyesq https://medium.com/@sethbradleyesq https://www.tiktok.com/@sethbradleyesq?lang=en